Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...

In treating hematologic malignancies, engineered T-cell therapy outperforms standard transplantation with respect to chronic ...

CEO Gina Chapman is also departing the company, which plans to review options for pursuing a reverse merger or other business ...

Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells ...

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed ...

(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...